Pds biotech completes enrollment in immune checkpoint inhibitor naÏve arm of versatile-002 phase 2 clinical trial in advanced hpv16 positive head and neck cancer

Company plans to initiate versatile-003 phase 3 clinical trial in late 2023 company plans to initiate versatile-003 phase 3 clinical trial in late 2023

PDSB Ratings Summary

PDSB Quant Ranking